[go: up one dir, main page]

ES2192273T3 - Procedimiento para producir compuestos de ecteinascidina. - Google Patents

Procedimiento para producir compuestos de ecteinascidina.

Info

Publication number
ES2192273T3
ES2192273T3 ES97942526T ES97942526T ES2192273T3 ES 2192273 T3 ES2192273 T3 ES 2192273T3 ES 97942526 T ES97942526 T ES 97942526T ES 97942526 T ES97942526 T ES 97942526T ES 2192273 T3 ES2192273 T3 ES 2192273T3
Authority
ES
Spain
Prior art keywords
ecteinascidine
procedure
compounds
produce
formation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97942526T
Other languages
English (en)
Inventor
Elias J Corey
David Gin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Application granted granted Critical
Publication of ES2192273T3 publication Critical patent/ES2192273T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN PROCEDIMIENTO SINTETICO PARA LA FORMACION DE COMPUESTOS DE ECTEINASCIDINA Y ESTRUCTURAS RELACIONADAS, COMO LAS SAFRAMICINAS. EN UNA REALIZACION ESPECIALMENTE PREFERIDA DE LA INVENCION, LA INVENCION PROPORCIONA UNA RUTA SINTETICA PARA LA FORMACION DE ECTEINASCIDINA 743 (1), QUE ES UN AGENTE ANTITUMORAL POTENTISIMO, DERIVADO DE ESPECIES MARINAS RARAS Y EXPLOTADO EN ENSAYOS QUIMICOS. EL PROCEDIMIENTO DE LA INVENCION ESTA CONTROLADO ENANTIOMERICA Y ESTEREOQUIMICAMENTE, ES CONVERGENTE Y CORTO. ASIMISMO, SE DESCRIBEN NUEVOS INTERMEDIARIOS DE DICHOS PROCEDIMIENTO, UTILES NO SOLO PARA LA SINTESIS TOTAL DE ECTEINASCIDINA 743, SINO TAMBIEN PARA OTROS COMPUESTOS DE ECTEINASCIDINA CONOCIDOS, INCLUYENDO DERIVADOS Y ANALOGOS DE LA MISMA.
ES97942526T 1996-09-18 1997-09-17 Procedimiento para producir compuestos de ecteinascidina. Expired - Lifetime ES2192273T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/715,541 US5721362A (en) 1996-09-18 1996-09-18 Process for producing ecteinascidin compounds

Publications (1)

Publication Number Publication Date
ES2192273T3 true ES2192273T3 (es) 2003-10-01

Family

ID=24874473

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97942526T Expired - Lifetime ES2192273T3 (es) 1996-09-18 1997-09-17 Procedimiento para producir compuestos de ecteinascidina.

Country Status (21)

Country Link
US (1) US5721362A (es)
EP (1) EP0931083B1 (es)
JP (1) JP4425995B2 (es)
KR (1) KR100358832B1 (es)
CN (1) CN1096463C (es)
AT (1) ATE232868T1 (es)
AU (1) AU738282B2 (es)
BR (1) BR9712073B1 (es)
CA (1) CA2266081C (es)
CZ (1) CZ299596B6 (es)
DE (1) DE69719201T2 (es)
DK (1) DK0931083T3 (es)
ES (1) ES2192273T3 (es)
HU (1) HU229407B1 (es)
IL (2) IL128993A0 (es)
NO (1) NO325345B1 (es)
NZ (1) NZ334704A (es)
PL (1) PL188572B1 (es)
PT (1) PT931083E (es)
RU (1) RU2194709C2 (es)
WO (1) WO1998012198A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE370148T1 (de) * 1998-04-06 2007-09-15 Univ Illinois Halbsynthetische ectein-ascidine
TR200003470T2 (tr) * 1998-05-11 2001-06-21 Pharama Mar, S.A. Ecteinascidin 743 Metabolitleri
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
GB9918178D0 (en) * 2000-05-15 1999-10-06 Pharma Mar Sa Synthetic methods
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
BG65893B1 (bg) * 1999-05-14 2010-04-30 Pharma Mar S.A. Полусинтетичен метод и нови съединения
US6686470B2 (en) * 2000-01-19 2004-02-03 The Trustees Of Columbia University In The City Of New York Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
NZ520635A (en) * 2000-02-11 2004-05-28 Harvard College Synthetic process for an intermediate for ecteinascidin and phthalascidin compounds
US6815544B2 (en) 2000-02-11 2004-11-09 President And Fellows Of Harvard College Synthetic process for an intermediate for ecteinascidin and phthalascidin compounds
US6569859B1 (en) 2000-02-22 2003-05-27 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
JP5219323B2 (ja) * 2000-04-12 2013-06-26 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍性エクチナサイジン誘導体
US7919493B2 (en) * 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
JP4942900B2 (ja) * 2000-05-15 2012-05-30 ファルマ・マール・ソシエダード・アノニマ エクチナサイジン化合物の製造のための合成方法
AU3956502A (en) 2000-11-03 2002-05-27 Harvard College Saframycins, analogues and uses thereof
JP4391083B2 (ja) * 2000-11-06 2009-12-24 ファルマ・マール・ソシエダード・アノニマ 効果的な抗腫瘍治療
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) * 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
JP4208469B2 (ja) * 2002-01-29 2009-01-14 独立行政法人科学技術振興機構 エクテナサイジン類の全合成方法、エクテナサイジン類に類縁構造を持つ前記全合成用中間体化合物類、及び該中間体化合物類の合成方法
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
US7183054B2 (en) 2003-06-03 2007-02-27 President And Fellows Of Harvard College Assay for identifying biological targets of polynucleotide-binding compounds
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
DK1689404T3 (da) * 2003-11-13 2009-01-26 Pharma Mar Sau Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
CA2545054A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
AU2005261860A1 (en) * 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of BRCA1
CN100396178C (zh) * 2004-08-06 2008-06-25 中国科学院海洋研究所 一种玻璃海鞘的全人工养殖方法及简易型连续投饵装置
CN101068596A (zh) * 2004-09-29 2007-11-07 法马马私人股份有限公司 艾可特耐思地作抗炎药
ATE430586T1 (de) * 2004-10-26 2009-05-15 Pharma Mar Sa Pegyliertes liposomales doxorubicin in kombination mit ecteinescidin 743
KR101188691B1 (ko) 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
CN101157929B (zh) * 2007-02-02 2012-05-23 中国科学院上海有机化学研究所 番红霉素的生物合成基因簇
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
EP2576569B1 (en) 2010-05-25 2015-01-14 Pharma Mar S.A. Synthetic process for the manufacture of ecteinascidin compounds and intermediates
PT2786756T (pt) 2010-11-12 2020-05-07 Pharma Mar Sa Terapia de combinação com um inibidor de topoisomerase
CN103304478B (zh) * 2013-06-28 2016-04-20 四川大学 一类合成renieramycins型生物碱的中间体及其制备方法
CN108084146B (zh) * 2013-10-29 2020-07-28 江苏盛迪医药有限公司 一种海鞘碱-743中间体的制备方法
CN103709101B (zh) * 2013-12-19 2016-06-29 四川大学 一类renieramycin G的合成中间体及其制备方法
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
CN111518110B (zh) 2019-02-01 2023-11-03 博瑞生物医药（苏州）股份有限公司 一种海鞘素化合物及其中间体的制备方法
CN110092802B (zh) * 2019-06-21 2022-01-07 爱斯特（成都）生物制药股份有限公司 一种制备曲贝替定中间体的方法
US20220315605A1 (en) * 2019-06-27 2022-10-06 Msn Laboratories Private Limited, R&D Center IMPROVED PROCESS FOR THE PREPARATON OF PURE (1'R,6R,6aR,7R,13S,14S,16R)-5-(ACETYLOXY)-3',4',6,6a,7,13,14,16-OCTAHYDRO-6',8,14-TRIHYDROXY-7',9-DIMETHOXY-4,10,23-TRIMETHYLSPIRO[6,16-(EPITHIOPROPANOXYMETH ANO)-7,13-IMINO-12H-1,3-DIOXOLO[7,8]ISOQUINO[3,2-b][3]BENZAZOCINE-20,1'(2'H)-ISOQUINOLIN]-19-ONE POLYMORPH THERE OF
CN118924689A (zh) 2019-11-21 2024-11-12 法马马有限公司 用鲁比卡丁制剂治疗小细胞肺癌的方法
CN114621245A (zh) * 2020-12-11 2022-06-14 江苏恒瑞医药股份有限公司 一种曲贝替定中间体的晶型及其制备方法
US12303506B2 (en) 2022-01-20 2025-05-20 Extrovis Ag Trabectedin composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
DE3923985C1 (es) * 1989-07-20 1990-06-28 Daimler-Benz Aktiengesellschaft, 7000 Stuttgart, De
GB2252781B (en) * 1991-02-14 1994-08-17 Sanwa Shutter Corp Architectural shutter curtain device
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins

Also Published As

Publication number Publication date
CN1237974A (zh) 1999-12-08
CZ91499A3 (cs) 1999-08-11
DE69719201T2 (de) 2003-12-11
KR20000036242A (ko) 2000-06-26
EP0931083B1 (en) 2003-02-19
DE69719201D1 (de) 2003-03-27
AU4420597A (en) 1998-04-14
PT931083E (pt) 2003-07-31
IL128993A (en) 2006-06-11
PL332206A1 (en) 1999-08-30
HUP0000068A3 (en) 2001-12-28
HUP0000068A2 (hu) 2000-06-28
NO991301L (no) 1999-05-14
PL188572B1 (pl) 2005-02-28
JP2001501196A (ja) 2001-01-30
JP4425995B2 (ja) 2010-03-03
CA2266081A1 (en) 1998-03-26
NZ334704A (en) 2000-09-29
US5721362A (en) 1998-02-24
ATE232868T1 (de) 2003-03-15
HU229407B1 (en) 2013-12-30
NO325345B1 (no) 2008-04-07
KR100358832B1 (ko) 2002-11-21
CN1096463C (zh) 2002-12-18
DK0931083T3 (da) 2003-05-26
BR9712073A (pt) 2002-01-15
AU738282B2 (en) 2001-09-13
CZ299596B6 (cs) 2008-09-17
IL128993A0 (en) 2000-02-17
EP0931083A1 (en) 1999-07-28
NO991301D0 (no) 1999-03-17
BR9712073B1 (pt) 2013-06-18
CA2266081C (en) 2006-12-12
EP0931083A4 (en) 2000-05-24
WO1998012198A1 (en) 1998-03-26
RU2194709C2 (ru) 2002-12-20

Similar Documents

Publication Publication Date Title
ES2192273T3 (es) Procedimiento para producir compuestos de ecteinascidina.
MX9709278A (es) Dipeptidos que promueven la liberacion de la hormona de crecimiento, composiciones que los contienen y uso de los mismos.
HN1998000157A (es) Agonistas de prostaglandinas
CO4910163A1 (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas
ATE217629T1 (de) Phosphonooxymethyl oder methylthiomethylether von taxanderivaten als antitumormittel
ES2149378T3 (es) Procedimiento para la sulfonilacion, sulfenilacion y fosforilacion de depsipeptidos ciclicos.
ES2195970T3 (es) L-ribavirina y usos de la misma.
CO5160262A1 (es) Formulaciones farmaceuticas de liberacion controlada
ES2172654T3 (es) Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe.
DE69313455D1 (de) Feuchthaltende lippenstiftzusammensetzungen
AR020345A1 (es) Pirazol-carboxanilidas, procedimiento para su obtencion, composiciones, empleo de dichos compuestos y procedimiento para la lucha contra microorganismos indeseables, y procedimiento para la obtencion de dichas composiciones.
SV1997000079A (es) Dihidrato d de olancepina ref. x- 11062t
GT199700009AA (es) Terapia combinada para la osteoporosis
DE69433784D1 (de) 9-(Substituiertes Glycyl)amido-6-(substituiert)-5-hydroxy-6-deoxytetracycline
ES2186720T3 (es) Composiciones para inhibir la reabsorcion osea mediada por osteoclastos.
ES2179386T3 (es) 1-arilpirazoles plaguicidas.
MY113806A (en) Antiparasitic marcfortines and paraherquamides
ES2184929T3 (es) Mezclas de organo-polisulfanos y procedimiento para la preparacion de mezclas de caucho que los contienen.
PA8452701A1 (es) Agonistas de prostaglandinas
TR199900310T2 (xx) Trombin inhibit�rleri
AR003119A1 (es) Composicion farmaceutica para tratar infecciones virosicas o inhibir el crecimiento de tumores o canceres que comprenden una mezcla de un n- clorofenilcarbamato o un n- clorofeniltiocarbamato y un n- fosfonoglicina y uso de dicha composicion farmaceutica para la manufactura de un medicamento para tratar infecciones virosicas o inhibir el crecimiento de tumores o canceres
DE69840415D1 (de) Haemasterlin analoge
ES2179138T3 (es) Poliisocianatos que presentan grupos alofanato basados en difenilmetanodiisocianato con grupos isocianato predominante o completamente bloqueados.
SE9801494D0 (sv) Novel use
AR002247A1 (es) Eleuterobina y analogos de la misma y composiciones que las comprenden.